Login to MyKarger

New to MyKarger? Click here to sign up.



Login with Facebook

Forgot your password?

Authors, Editors, Reviewers

For Manuscript Submission, Check or Review Login please go to Submission Websites List.

Submission Websites List

Institutional Login
(Shibboleth or Open Athens)

For the academic login, please select your country in the dropdown list. You will be redirected to verify your credentials.

Editorial

Free Access

Head and Neck Cancer - New Insights into a Heterogeneous Disease

Klussmann J.P.

Author affiliations

Department of Otorhinolaryngology, Head and Neck Surgery, University of Gießen, Gießen, Germany

Corresponding Author

Univ.-Prof. Dr. med. Jens Peter Klussmann

Department of Otorhinolaryngology, Head and Neck Surgery

University of Gießen

Klinikstraße 33, 35385 Gießen, Germany

jens.p.klussmann@hno.med.uni-giessen.de

Related Articles for ""

Oncol Res Treat 2017;40:318-319

The large majority of head and neck cancers are squamous cell carcinomas (HNSCC) that arise at the mucosal linings of the upper aerodigestive tract, suggesting a homogeneous disease. However, HNSCC are remarkably heterogeneous. They include several subclassifications in relation to anatomic location, etiology, and molecular findings. In Germany, 4,532 and 12,992 new HNSCC cases in women and men, respectively, were counted in 2013. These HNSCC developed at different locations, i.e., oral cavity, pharynx, and larynx [1]. The 5-year overall survival for all locations is still poor and is estimated at 51% for men and 61% for women in Germany. Historically, HNSCC have been linked to tobacco and alcohol consumption. Over the past decades, the overall incidence of HNSCC has been decreasing. In contrast to that, the incidence of oropharyngeal cancers is rising, which is related to a strong increase of human papillomavirus(HPV)-associated cancers in western countries. The reason for this increase might be a sexual transmission of HPV decades before cancer development. These cancers are now identified as a distinct tumor entity, with many differences in comparison to HPV-negative HNSCC regarding their cellular, biological, and clinical characteristics. The identification of HPV-related HNSCC by molecular biology and recently omics approaches has disclosed the heterogeneity of HNSCC and thus has contributed to a new classification of these tumors. Strikingly, it became evident that HPV-related oropharyngeal cancers showed a significantly better response to established treatment modalities resulting in an improved overall survival. Therefore, the HPV status can be regarded as one of the most accurate prognostic biomarkers in HNSCC, and p16-immunostaining became a reliable surrogate marker for the HPV status. In line with this, the latest version of the ‘AJCC Cancer Staging Manual' [2] includes new staging rules for HPV-positive cancer.

Despite improvements in diagnosis and therapy, morbidity and mortality have remained high and appropriate treatment of patients still is a major challenge. Most cases are diagnosed with locally advanced disease, and multimodal treatment consists of concomitant chemoradiotherapy or surgery followed by risk-adapted radio(chemo)therapy. Although it is conceivable that distinct patient subgroups might benefit from treatment de-escalation (e.g., HPV-related HNSCC) or targeted therapy, effective personalized treatment options are not yet in clinical use for HNSCC.

The aim of this issue of Oncology Research and Treatment is to highlight new insights into the biology of HNSCC, to discuss their possible implications for established treatment modalities, to point to future therapeutic developments, and to call attention to open questions which should be addressed by clinical trials. Jou and Hess [3] focused on recent data derived from integrative genomics analysis and multi-scale modeling approaches regarding the biological and clinical diversity of HNSCC. Wagner et al. [4] gave an overview of the newly recognized tumor entity ‘HPV-related HNSCC'. Semrau [5] discussed modern treatment technologies and new developments of radiation oncology. In their original article, Wuerdemann et al. [6] compared the outcome of patient cohorts with HPV-related and -unrelated oropharyngeal cancers treated with primary surgery. Schuler at al. [7] outlined novel treatment options for HNSCC, especially in the field of immunotherapy.

Disclosure Statement

The author declares no conflict of interest.


References

  1. Robert Koch-Institut: Bericht zum Krebsgeschehen in Deutschland 2016. Berlin, Robert Koch-Institut, 2016.
  2. Amin MB, Edge SB, Greene FL, et al (eds): AJCC Cancer Staging Manual, ed 8. New York, Springer, 2017.
  3. Jou A, Hess J: Epidemiology and molecular biology of head and neck cancer. Oncol Res Treat 2017;40:DOI: 10.1159/000477127.
  4. Wagner S, Sharma S, Wuerdemann N, et al: Human papillomavirus-related head and neck cancer. Oncol Res Treat 2017;40:DOI: 10.1159/000477252.
  5. Semrau R: The role of radiotherapy in the definitive and postoperative treatment of advanced head and neck cancer. Oncol Res Treat 2017;40:DOI: 10.1159/ 000477128.
  6. Wuerdemann N, Wittekindt C, Sharma S, et al: Risk factors for overall survival outcome in surgically treated human papillomavirus-negative and -positive patients with oropharyngeal cancer. Oncol Res Treat 2017;40:DOI: 10.1159/000477097.
  7. Schuler P, Laban S, Doescher J, et al: Novel treatment options in head and neck cancer. Oncol Res Treat 2017;40:DOI: 10.1159/000477254.

Author Contacts

Univ.-Prof. Dr. med. Jens Peter Klussmann

Department of Otorhinolaryngology, Head and Neck Surgery

University of Gießen

Klinikstraße 33, 35385 Gießen, Germany

jens.p.klussmann@hno.med.uni-giessen.de


Article / Publication Details

Received: May 04, 2017
Accepted: May 04, 2017
Published online: May 17, 2017
Issue release date: June 2017

Number of Print Pages: 2
Number of Figures: 0
Number of Tables: 0

ISSN: 2296-5270 (Print)
eISSN: 2296-5262 (Online)

For additional information: https://www.karger.com/ORT


Copyright / Drug Dosage / Disclaimer

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

References

  1. Robert Koch-Institut: Bericht zum Krebsgeschehen in Deutschland 2016. Berlin, Robert Koch-Institut, 2016.
  2. Amin MB, Edge SB, Greene FL, et al (eds): AJCC Cancer Staging Manual, ed 8. New York, Springer, 2017.
  3. Jou A, Hess J: Epidemiology and molecular biology of head and neck cancer. Oncol Res Treat 2017;40:DOI: 10.1159/000477127.
  4. Wagner S, Sharma S, Wuerdemann N, et al: Human papillomavirus-related head and neck cancer. Oncol Res Treat 2017;40:DOI: 10.1159/000477252.
  5. Semrau R: The role of radiotherapy in the definitive and postoperative treatment of advanced head and neck cancer. Oncol Res Treat 2017;40:DOI: 10.1159/ 000477128.
  6. Wuerdemann N, Wittekindt C, Sharma S, et al: Risk factors for overall survival outcome in surgically treated human papillomavirus-negative and -positive patients with oropharyngeal cancer. Oncol Res Treat 2017;40:DOI: 10.1159/000477097.
  7. Schuler P, Laban S, Doescher J, et al: Novel treatment options in head and neck cancer. Oncol Res Treat 2017;40:DOI: 10.1159/000477254.
Figures

Tables